| Cat. No. |
Product Name |
Information |
| PC-Ab1085 |
Dupilumab
|
Dupilumab (REGN-668, SAR-231893) is a human monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab down-regulates TH2 inflammation in a variety of allergic disorders, including atopic dermatitis, asthma and possibly other allergic diseases. Besides, Dupilumab was shown to inhibit IgE production by ex-vivo B cells induced by IL-4 treatment.. |
| PC-Ab1084 |
Clazakizumab
|
Clazakizumab (ALD518, BMS 945429) a humanized anti–IL-6 mAb, targets human IL-6 with an affinity of 4 pM, binds circulating IL-6 cytokine rather than the IL-6 receptor 10, 11, blocking both classic signaling and trans-signaling. significantly improves disease activity in rheumatoid arthritis (RA). It has also been evaluated for the treatment of non-small cell lung cancer (NSCLC) and patients with head and neck cancer.. |
| PC-Ab1083 |
Aducanumab
|
Aducanumab (BIIB037) is a monoclonal antibody selectively targets aggregated Aβ, binds to the N-terminus of Aβ peptide and recognizes aggregated forms of Aβ, including epitopes or conformations present in soluble and insoluble oligomers. The FDA approved aducanumab under accelerated approval based on reduction in amyloid plaques in Alzheimer's disease (AD).. |
| PC-Ab1082 |
Varlilumab
|
Varlilumab (CDX-1127) is a novel, first-in-class fully human IgG1 kappa anti-CD27 monoclonal antibody that acts as an agonist of CD27 by interaction with the CD70-binding site. Varlilumab (CDX-1127) stimulates the CD27 pathway, which results in T-cell activation and antitumor activity in tumor models.. |
| PC-Ab1081 |
Etokimab
|
Etokimab (ANB-020) is an IgG1 anti-IL-33 monoclonal antibody. Interleukin-33 (IL-33) is a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases.. |
| PC-Ab1080 |
Amatuximab
|
Mesothelin (MSLN) is a glycosylphosphatidylinositol-anchored cell-surface protein that may function as a cell adhesion protein. This protein is overexpressed in epithelial mesotheliomas, ovarian cancers and in specific squamous cell carcinomas. Amatuximab (MORAb-009) blocks the binding of mesothelin to CA 125 and thus could be used also as a strategy to prevent tumor metastasis.. |
| PC-Ab1079 |
Brodalumab
|
Brodalumab (AMG-827, KHK-4827) is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.. |
| PC-Ab1078 |
Anti-human SIGLEC15 mAb, 5G-12
|
Anti-Human SIGLEC15 (5G-12) is a high affinity humanized IgG1 mAb specific for SIGLEC15 (S15, Sialic Acid-Binding Ig-Like Lectin 15), blocks Siglec-15-mediated suppression of murine OT-I responses to 293T-K b OVA-S15 + or OVA 257-264-pulsed mouse primary macrophages, inhibits the growth of established tumors in murine models.. |
| PC-Ab1077 |
Anti-mouse PD-1 mAb, RMP1-14
|
Anti-Mouse PD-1 (RMP1-14 Biosimilar) is a recombinant mouse mAb against murine PD-1 for in vivo use. In ABC-DLBCL model showed that combined venetoclax and RMP1-14 significantly increased the overall survival of lymphoma bearing animals.. |
| PC-Ab1076 |
Anti-mouse CTLA4 mAb
|
. |
| PC-Ab1075 |
Mavrilimumab
|
Mavrilimumab (KPL-301, CAM3001) is a monoclonal antibody to GM-CSF receptor-α chain, and competitive antagonist of GM-CSF signaling. Mavrilimumab also is a monoclonal antibody (mAb) that may be helpful in some cases with COVID-19. Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVI |
| PC-Ab1074 |
MDX-1342
|
MDX-1342 is a fully human monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) effector function, targeting CD19-membrane receptor which is highly expressed on malignant chronic lymphocytic leukemia (CLL) cells. MDX-1342 blocks activation of B cell stimulation, decreasing the number of cancerous B cell clones.. |
